PE20190335A1 - Receptores de celulas t - Google Patents
Receptores de celulas tInfo
- Publication number
- PE20190335A1 PE20190335A1 PE2018001971A PE2018001971A PE20190335A1 PE 20190335 A1 PE20190335 A1 PE 20190335A1 PE 2018001971 A PE2018001971 A PE 2018001971A PE 2018001971 A PE2018001971 A PE 2018001971A PE 20190335 A1 PE20190335 A1 PE 20190335A1
- Authority
- PE
- Peru
- Prior art keywords
- tcr
- alpha
- beta
- seq
- variable domain
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 abstract 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000012737 microarray-based gene expression Methods 0.000 abstract 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 230000009258 tissue cross reactivity Effects 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 108010012015 GVYDGREHTV Proteins 0.000 abstract 1
- 102000011786 HLA-A Antigens Human genes 0.000 abstract 1
- 108010075704 HLA-A Antigens Proteins 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
Referido a receptores de celulas T (TCR) que tiene la propiedad de unirse a un complejo GVYDGREHTV (SEQ ID NO:1) HLA-A 02 y que comprende un dominio variable de cadena beta de TCR, en donde el domino variable de cadena alfa comprende una secuencia de aminoacidos que tiene al menos una identidad del 90% con los aminoacidos 1-113 de la SEQ ID NO:2, y/o el dominio variable de cadena beta comprende una secuencia de aminoacidos que tiene al menos una identidad del 90% con los aminoacidos 1-116 de la SEQ ID NO:3. Dichos TCR pueden comprender mutaciones no naturales dentro de los dominios variables alfa y/o beta con respecto a un TCR de MAGE A4 nativo. Dichos TCR pueden comprender mutaciones no naturales dentro de los dominios variables alfa y/o beta con respecto a un TCR de MAGE A4 nativo. Tambien se refiere a un acido nucleico que codifica una cadena alfa de TCR, un vector de expresion, una celula que alberga al vector, una celula no natural y/o purificada y/o modificada, una composicion farmaceutica y uso como nuevos reactivos inmunoterapeuticos para el tratamiento de enfermedades malignas
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606009 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190335A1 true PE20190335A1 (es) | 2019-03-07 |
Family
ID=58548761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002239A PE20240693A1 (es) | 2016-04-08 | 2017-04-07 | Receptores de celulas t |
| PE2018001971A PE20190335A1 (es) | 2016-04-08 | 2017-04-07 | Receptores de celulas t |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002239A PE20240693A1 (es) | 2016-04-08 | 2017-04-07 | Receptores de celulas t |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11505590B2 (es) |
| EP (2) | EP4023668A1 (es) |
| JP (1) | JP7254519B2 (es) |
| KR (1) | KR102473964B1 (es) |
| CN (1) | CN109563148B (es) |
| AU (2) | AU2017246693B2 (es) |
| BR (1) | BR112018070741A2 (es) |
| CA (1) | CA3020214A1 (es) |
| CL (1) | CL2018002859A1 (es) |
| CO (1) | CO2018011972A2 (es) |
| CR (1) | CR20180531A (es) |
| DK (1) | DK3440105T3 (es) |
| ES (1) | ES2914648T3 (es) |
| HR (1) | HRP20220865T1 (es) |
| HU (1) | HUE059159T2 (es) |
| IL (2) | IL308831A (es) |
| LT (1) | LT3440105T (es) |
| MA (1) | MA44608B1 (es) |
| MD (1) | MD3440105T2 (es) |
| MX (1) | MX2018012318A (es) |
| MY (1) | MY198621A (es) |
| PE (2) | PE20240693A1 (es) |
| PH (1) | PH12018502158A1 (es) |
| PL (1) | PL3440105T3 (es) |
| PT (1) | PT3440105T (es) |
| RS (1) | RS63371B1 (es) |
| SG (1) | SG11201808797XA (es) |
| SI (1) | SI3440105T1 (es) |
| WO (1) | WO2017175006A1 (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2788188T5 (es) * | 2016-04-08 | 2023-10-24 | Adaptimmune Ltd | Receptores de linfocitos T |
| AU2017248120B2 (en) * | 2016-04-08 | 2022-07-21 | Adaptimmune Limited | T cell receptors |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| WO2019195492A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| LT3911298T (lt) | 2019-01-17 | 2023-12-27 | Immunocore Limited | Kompozicijos |
| GB201901305D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Specific binding molecules |
| GB201901306D0 (en) | 2019-01-30 | 2019-03-20 | Immunocore Ltd | Multi-domain binding molecules |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| AU2020295401A1 (en) * | 2019-06-18 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | MAGE-A4 T cell receptors and methods of use thereof |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| CA3161390A1 (en) | 2019-12-18 | 2021-06-24 | Tina WEINZIERL | Antibodies binding to hla-a2/mage-a4 |
| EP4103285A2 (en) | 2020-02-14 | 2022-12-21 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| JP2023527293A (ja) * | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US11912771B2 (en) | 2021-03-09 | 2024-02-27 | Cdr-Life Ag | MAGE-A4 peptide-MHC antigen binding proteins |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
| TW202328212A (zh) | 2021-12-01 | 2023-07-16 | 英商英美偌科有限公司 | Ｍａｇｅ—ａ４陽性癌症之治療 |
| WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ｉｋａｒｏｓ鋅指家族降解劑及其用途 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN117106060A (zh) * | 2022-05-17 | 2023-11-24 | 香雪生命科学技术（广东）有限公司 | 一种识别mage的高亲和力t细胞受体及其应用 |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024038165A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Ltd | T cell receptor fusion proteins specific for mage a4 |
| WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024056758A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039482A1 (en) | 1997-03-07 | 1998-09-11 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| EP1247095B1 (en) | 1999-12-06 | 2008-10-15 | Board Of Trustees Of The University Of Illinois | High affinity tcr proteins and methods |
| AU2001232204A1 (en) | 2000-02-22 | 2001-09-03 | Ahuva Nissim | Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof |
| PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
| WO2004023973A2 (en) | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| NZ539225A (en) | 2002-10-09 | 2006-09-29 | Avidex Ltd | Single chain recombinant T cell receptors |
| NZ570811A (en) | 2002-11-09 | 2009-11-27 | Immunocore Ltd | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| NZ584523A (en) | 2005-04-01 | 2010-11-26 | Immunocore Ltd | High affinity hiv t cell receptors |
| KR101130597B1 (ko) | 2005-09-13 | 2012-04-02 | 다카라 바이오 가부시키가이샤 | Ｔ 세포 리셉터 및 그 리셉터를 코드하는 핵산 |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| EP2755997B1 (en) | 2011-09-15 | 2018-07-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| BR112014008691A2 (pt) * | 2011-10-14 | 2017-06-13 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos para cd1d |
| JP6254528B2 (ja) | 2011-10-28 | 2017-12-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 遺伝子改変ｔ細胞受容体マウス |
| GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
| EP2951202B1 (en) * | 2013-01-29 | 2020-04-08 | Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; | High avidity binding molecules recognizing mage-a1 |
| US10000546B2 (en) | 2013-03-13 | 2018-06-19 | Health Research, Inc. | Compositions and method for use of recombinant T cell receptors for direct recognition of tumor antigen |
| EP3166647A4 (en) * | 2014-07-09 | 2018-02-14 | The Regents of the University of California | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof |
| US10538572B2 (en) | 2014-08-04 | 2020-01-21 | Fred Hutchinson Cancer Research Center | T cell immunotherapy specific for WT-1 |
| CA2925589A1 (en) | 2015-04-13 | 2016-10-13 | Pfizer Inc. | Chimeric antigen receptors targeting b-cell maturation antigen |
| EP4357454A2 (en) | 2016-03-16 | 2024-04-24 | Immatics Biotechnologies GmbH | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| BR112018070073A2 (pt) | 2016-04-01 | 2019-02-12 | Kite Pharma, Inc. | receptores de antígeno quimérico e célula t e métodos de uso |
-
2017
- 2017-04-07 MX MX2018012318A patent/MX2018012318A/es unknown
- 2017-04-07 JP JP2018552859A patent/JP7254519B2/ja active Active
- 2017-04-07 EP EP21211000.1A patent/EP4023668A1/en active Pending
- 2017-04-07 SG SG11201808797XA patent/SG11201808797XA/en unknown
- 2017-04-07 KR KR1020187032374A patent/KR102473964B1/ko active IP Right Grant
- 2017-04-07 MY MYPI2018001690A patent/MY198621A/en unknown
- 2017-04-07 LT LTEPPCT/GB2017/050985T patent/LT3440105T/lt unknown
- 2017-04-07 MA MA44608A patent/MA44608B1/fr unknown
- 2017-04-07 CR CR20180531A patent/CR20180531A/es unknown
- 2017-04-07 BR BR112018070741-4A patent/BR112018070741A2/pt unknown
- 2017-04-07 PL PL17717845.6T patent/PL3440105T3/pl unknown
- 2017-04-07 AU AU2017246693A patent/AU2017246693B2/en active Active
- 2017-04-07 CN CN201780035758.0A patent/CN109563148B/zh active Active
- 2017-04-07 EP EP17717845.6A patent/EP3440105B1/en active Active
- 2017-04-07 MD MDE20190184T patent/MD3440105T2/ro unknown
- 2017-04-07 PT PT177178456T patent/PT3440105T/pt unknown
- 2017-04-07 ES ES17717845T patent/ES2914648T3/es active Active
- 2017-04-07 IL IL308831A patent/IL308831A/en unknown
- 2017-04-07 PE PE2023002239A patent/PE20240693A1/es unknown
- 2017-04-07 SI SI201731151T patent/SI3440105T1/sl unknown
- 2017-04-07 IL IL262144A patent/IL262144B2/en unknown
- 2017-04-07 US US16/092,174 patent/US11505590B2/en active Active
- 2017-04-07 DK DK17717845.6T patent/DK3440105T3/da active
- 2017-04-07 HR HRP20220865TT patent/HRP20220865T1/hr unknown
- 2017-04-07 PE PE2018001971A patent/PE20190335A1/es unknown
- 2017-04-07 WO PCT/GB2017/050985 patent/WO2017175006A1/en active Application Filing
- 2017-04-07 RS RS20220652A patent/RS63371B1/sr unknown
- 2017-04-07 CA CA3020214A patent/CA3020214A1/en active Pending
- 2017-04-07 HU HUE17717845A patent/HUE059159T2/hu unknown
-
2018
- 2018-10-08 PH PH12018502158A patent/PH12018502158A1/en unknown
- 2018-10-08 CL CL2018002859A patent/CL2018002859A1/es unknown
- 2018-11-02 CO CONC2018/0011972A patent/CO2018011972A2/es unknown
-
2022
- 2022-10-13 US US18/046,408 patent/US20230322895A1/en active Pending
- 2022-10-19 AU AU2022256131A patent/AU2022256131A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190335A1 (es) | Receptores de celulas t | |
| ZA202306640B (en) | T cell receptors | |
| CL2020001181A1 (es) | Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos. | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| CR20180492A (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
| PH12019500750A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
| BR112019018307A2 (pt) | Plataforma para identificação de peptídeos imunogênicos baseada em população | |
| MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| PE20191648A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| MY196179A (en) | T Cell Receptors Specific for the NY-ESO-1 Tumor Antigen-Hla-A*02 Complex | |
| UY36539A (es) | Proteínas de unión a icos | |
| NZ715038A (en) | T cell receptors | |
| BR112017003104A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico anti-cd123 | |
| MX2019008346A (es) | Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos. | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| BR112017000939A2 (pt) | tratamento de câncer usando um receptor antigênico quimérico de cll-1 | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| PE20191248A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| CL2019003426A1 (es) | Nuevos péptidos (seq id n°174), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| MY193807A (en) | T-cell receptor and uses thereof | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos | |
| MX2016007950A (es) | Receptor de celulas t que se une a alwgpdpaaa, derivado de proteína pre-proinsulina (ppi) humana. |